TY - JOUR
T1 - Inflammation
T2 - Roles in aging and sarcopenia
AU - Jensen, Gordon L.
N1 - Funding Information:
The pathophysiology of sarcopenia is undoubtedly multifactorial, but research findings suggest that sarcopenia is a low-level, smoldering inflammatory state driven by cytokines and oxidative stress. Successful interventions are therefore likely to require a multifaceted approach that also targets inflammation. Primary therapy for adults with sarcopenia should include resistance exercise, which has been demonstrated to improve both muscle mass and strength. A key question is whether sarcopenia is truly a distinct syndrome or actually a milder form of a cachexia continuum. Improved understanding can help to clarify appropriate approaches to prevention and treatment. Financial disclosure: none declared. The 2008 Intersociety Research Workshop: Nutrition and Inflammation: Research Makes the Connection, was supported by grant number U13DK064190 from the National Institute of Diabetes and Digestive and Kidney Diseases. The content is solely the responsibility of the authors and does not necessarily represent the official view of the National Institute of Diabetes and Digestive and Kidney Diseases or the National Institutes of Health. 1 Jensen GL. Inflammation as the key interface of the medical and nutrition universes: a provocative examination of the future of clinical nutrition and medicine. JPEN J Parenter Enteral Nutr . 2006 ; 30 : 453 -463. 2 Roubenoff R. Catabolism of aging: is it an inflammatory process? Curr Opin Clin Nutr Metab Care . 2003 ; 6 : 295 -299. 3 Rosenberg IH. Summary comments. Am J Clin Nutr . 1989 ; 50 : 1231 -1233. 4 Greenlund LJS, Nair KS. Sarcopenia-consequences, mechanisms, and potential therapies. Mech Aging Develop . 2003 ; 124 : 287 -299. 5 Roubenoff R. Sarcopenia and its implications for the elderly. Eur J Clin Nutr . 2000 ; 54 ( suppl 3 ) LS40 -LS47. 6 Dirks AJ, Leeuwenburgh C. Tumor necrosis factor α signaling in skeletal muscle: effects of age and caloric restriction. J Nutr Biochem . 2006 ; 17 : 501 -508. 7 Baumgartner RN, Koehler KM, Romero LJ, Lindeman RD, Gary PJ. Epidemiology of sarcopenia in elderly people in New Mexico. Am J Epidemiol . 1998 ; 147 : 744 -763. 8 Thomas DR. Loss of skeletal muscle mass in aging: examining the relationship of starvation, sarcopenia and cachexia. Clin Nutr . 2007 ; 26 : 389 -399. 9 Janssen I, Shepard DS, Katzmarzyk PT, Roubenoff R. The healthcare costs of sarcopenia in the United States. J Am Geriatr Soc . 2004 ; 52 : 80 -85. 10 Morley JE, Baumgartner RN, Roubenoff R, Mayer K, Nair KS. Sarcopenia. J Lab Clin Med . 2001 ; 137 : 231 -243. 11 Marzetti E, Leeuwenburgh C. Skeletal muscle apoptosis, sarcopenia and frailty at old age. Expt Gerontol . 2006 ; 41 : 1234 -1238. 12 Payette H, Roubenoff R, Jacques PF, et al. Insulin-like growth factor–1 and interleukin 6 predict sarcopenia in very old community-living men and women: the Framingham Heart Study. J Am Geriatr Soc . 2003 ; 51 : 1237 -1243. 13 Reuben DB, Judd-Hamilton L, Harris TB, Seeman TE. The associations between physical activity and inflammatory markers in high-functioning older persons: MacAthur studies of successful aging. J Am Geriatr Soc . 2003 ; 51 : 1125 -1130. 14 Schaap L, Pluijm SMF, Deeg DJH, Visser M. Inflammatory markers and loss of muscle mass (sarcopenia) and strength. Am J Med . 2006 ; 119 : 526.e9 -526.e17. 15 Hubbard RE, O'Mahony MS, Calver BL, Woodhouse KW. Nutrition, inflammation, and leptin levels in aging and frailty. J Am Geriatr Soc . 2008 ; 56 : 279 -284. 16 Roubenoff R. Sarcopenic obesity: does muscle loss cause fat gain? Lessons from rheumatoid arthritis and osteoarthritis. Ann NY Acad Sci . 2000 ; 903 : 553 -557. 17 Cesari M, Kritchevsky SB, Baumgartner RN, et al. Sarcopenia, obesity, and inflammation: results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors study. Am J Clin Nutr . 2005 ; 82 : 428 -434. 18 Jensen GL, Friedmann J. Obesity is associated with functional decline among community dwelling rural older persons. J Am Geriatr Soc . 2002 ; 50 : 918 -923. 19 Jensen GL, Silver HJ, Roy MA, Callahan E, Still C, Dupont W. Obesity is a risk factor for reporting homebound status among community dwelling older persons. Obesity . 2006 ; 14 : 509 -517. 20 Goodpaster BH, Stenger VA, Boada F, et al. Skeletal muscle lipid concentration quantified by magnetic resonance imaging. Am J Clin Nutr . 2004 ; 79 : 748 -754. 21 Cororan MP, Lamon-Fava S, Fielding RA. Skeletal muscle deposition and insulin resistance: effect of dietary fatty acids and exercise. Am J Clin Nutr . 2007 ; 85 : 662 -677. 22 Alley DE, Seeman TE, Ki Kim J, Karlamanga A, Hu P, Crimmins EM. Socioeconomic status and C-reactive protein levels in the US population: NHANES IV. Brain Behav Immun . 2006 ; 20 : 498 -504. 23 Fiatarone MA, O'Neill EF, Ryan ND, et al. Exercise training and nutritional supplementation for physical frailty in very elderly people. N Engl J Med . 1994 ; 330 : 1969 -1975. 24 Fontana L, Klein S. Aging, adiposity, and calorie restriction. JAMA . 2007 ; 297 : 986 -994. 25 Clement K, Viguerie N, Poitou C, et al. Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects. FASEB J . 2004 ; 18 : 1657 -1669. 26 Papadakis MA, Grady D, Black D, et al. Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann Intern Med . 1996 ; 124 : 708 -716. 27 Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab . 1999 ; 84 : 2647 -2653. 28 Solomon AM, Bouloux PMG. Modifying muscle mass: the endocrine perspective. J Endocrinol . 2006 ; 191 : 349 -360. 29 Sanborn WJ. New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease. Rev Gastroenterol Disord . 2005 ; 5 : 10 -18. 30 Holtmann MH, Neurath MF. Anti-TNF strategies in stenosing and fistulizing Crohn's disease. Int J Colorectal Dis . 2005 ; 20 : 1 -8. 31 Brown MA. Antibody treatments of inflammatory arthritis. Curr Med Chem . 2005 ; 12 : 2943 -2946. 32 Semba RD, Lauretani F, Ferrucci L. Carotenoids as protection against sarcopenia in older adults. Arch Biochem Biophys . 2007 ; 458 : 141 -145. 33 Semba RD, Blaum C, Guralnik JM, et al. Carotenoid and vitamin E status are associated with indicators of sarcopenia among older women living in the community. Aging Clin Exp Res . 2003 ; 15 : 482 -487. 34 Cesari M, Oahor B, Bartali B, et al. Antioxidants and physical performance in elderly persons: the Invecchiare in Chianti (InCHIANTI) study. Am J Clin Nutr . 2004 ; 79 : 289 -294. 35 Semba RD, Varadhan B, Bartali B, et al. Low serum carotenoids and development of severe walking disability among older women living in the community: the Women's Health and Aging Study I. Age Ageing . 2007 ; 36 : 62 -67.
PY - 2008/11
Y1 - 2008/11
N2 - Aging is associated with inflammatory chronic conditions such as obesity, cardiovascular disease, insulin resistance, and arthritis. Sarcopenia-muscle loss with aging-is multifactorial with contributing factors that may include loss of α-motor neuron input, changes in anabolic hormones, decreased intake of dietary protein, and decline in physical activity. Research findings suggest that sarcopenia is a smoldering inflammatory state driven by cytokines and oxidative stress. Elevated levels of interleukin-6 and C-reactive protein are often detected. Sarcopenic obesity manifests the added inflammatory burden of adiposity and associated adipokines. Potential interventions for sarcopenia include nutritional supplements, physical activity/resistance exercise, caloric restriction, anabolic hormones, anti-inflammatory agents, and antioxidants. A key question is whether sarcopenia is truly a distinct syndrome or a milder form of a cachexia continuum.
AB - Aging is associated with inflammatory chronic conditions such as obesity, cardiovascular disease, insulin resistance, and arthritis. Sarcopenia-muscle loss with aging-is multifactorial with contributing factors that may include loss of α-motor neuron input, changes in anabolic hormones, decreased intake of dietary protein, and decline in physical activity. Research findings suggest that sarcopenia is a smoldering inflammatory state driven by cytokines and oxidative stress. Elevated levels of interleukin-6 and C-reactive protein are often detected. Sarcopenic obesity manifests the added inflammatory burden of adiposity and associated adipokines. Potential interventions for sarcopenia include nutritional supplements, physical activity/resistance exercise, caloric restriction, anabolic hormones, anti-inflammatory agents, and antioxidants. A key question is whether sarcopenia is truly a distinct syndrome or a milder form of a cachexia continuum.
UR - http://www.scopus.com/inward/record.url?scp=54249117707&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=54249117707&partnerID=8YFLogxK
U2 - 10.1177/0148607108324585
DO - 10.1177/0148607108324585
M3 - Article
C2 - 18974248
AN - SCOPUS:54249117707
SN - 0148-6071
VL - 32
SP - 656
EP - 659
JO - Journal of Parenteral and Enteral Nutrition
JF - Journal of Parenteral and Enteral Nutrition
IS - 6
ER -
